|
1
|
Bertoni F, Tarantelli C, Spriano F, Cascione L, Civanelli E, Cannas E, Mensah A, Arribas A, Napoli S, Rinaldi A, Stathis A, Niewola K, Di Conza G, Lahn M, Santoro A, Carlo-Stella C. 53P Characterization of the non-ATP competitive PI3Kdelta inhibitor IOA-244 in lymphoma models: From single agent to combination screen and clinical investigation. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.100911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/10/2023] Open
|
|
2
|
Tarantelli C, Spriano F, Cascione L, Civanelli E, Cannas E, Mensah A, Arribas A, Rinaldi A, Stathis A, Di Conza G, Niewola-Staszkowska K, Lahn M, Bertoni F. Non-ATP competitive inhibition of PI3Kδ with IOA-244 shows anti-lymphoma activity. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01012-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
|
3
|
Arribas A, Napoli S, Cascione L, Sartori G, Gaudio E, Tarantelli C, Mensah A, Spriano F, Zucchetto A, Rossi F, Rinaldi A, Jovic S, Stathis A, Stussi G, Gattei V, Brown J, Esteller M, Zucca E, Rossi D, Bertoni F. 842P Secreted factors determine resistance to idelalisib in splenic marginal zone lymphoma (MZL) models. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
|
4
|
Arribas A, Napoli S, Cascione L, Gaudio E, Bordone-Pittau R, Barreca M, Sartori G, Chiara T, Spriano F, Rinaldi A, Stathis A, Stussi G, Rossi D, Emanuele Z, Bertoni F. Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)31181-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
|
5
|
Tarantelli C, Spriano F, Golino G, Gaudio E, Scalise L, Cascione L, Zucca E, van Berkel P, Stathis A, Zammarchi F, Bertoni F. THE ANTIBODY-DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT-402) TARGETING CD19 SHOWS STRONG IN VITRO
ANTI-LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION. Hematol Oncol 2019. [DOI: 10.1002/hon.90_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- C. Tarantelli
- Lymphoma Genomics; Università della Svizzera Italiana, Institute of Oncology Research; Bellinzona Switzerland
| | - F. Spriano
- Lymphoma Genomics; Università della Svizzera Italiana, Institute of Oncology Research; Bellinzona Switzerland
| | - G. Golino
- Lymphoma Genomics; Università della Svizzera Italiana, Institute of Oncology Research; Bellinzona Switzerland
| | - E. Gaudio
- Lymphoma Genomics; Università della Svizzera Italiana, Institute of Oncology Research; Bellinzona Switzerland
| | - L. Scalise
- Lymphoma Genomics; Università della Svizzera Italiana, Institute of Oncology Research; Bellinzona Switzerland
| | - L. Cascione
- Lymphoma Genomics; Università della Svizzera Italiana, Institute of Oncology Research; Bellinzona Switzerland
| | - E. Zucca
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - P. van Berkel
- Pharmacology; ADC Therapeutics; London United Kingdom
| | - A. Stathis
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Zammarchi
- Pharmacology; ADC Therapeutics; London United Kingdom
| | - F. Bertoni
- Lymphoma Genomics; Università della Svizzera Italiana, Institute of Oncology Research; Bellinzona Switzerland
| |
Collapse
|
|
6
|
Tarantelli C, Lange M, Gaudio E, Cascione L, Spriano F, Kwee I, Arribas A, Rinaldi A, Jourdan T, Berthold M, Margheriti F, Gritti G, Rossi D, Stathis A, Liu N, Zucca E, Politz O, Bertoni F. COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B- AND T-CELL LYMPHOMAS. Hematol Oncol 2019. [DOI: 10.1002/hon.127_2630] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- C. Tarantelli
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - M. Lange
- Pharmaceuticals Division - Therapeutic Research Groups Oncology; Bayer AG; Leverkusen Germany
| | - E. Gaudio
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - L. Cascione
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - F. Spriano
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - I. Kwee
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - A. Arribas
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - A. Rinaldi
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - T. Jourdan
- Pharmaceuticals Division - Therapeutic Research Groups Oncology; Bayer AG; Leverkusen Germany
| | - M. Berthold
- Pharmaceuticals Division - Therapeutic Research Groups Oncology; Bayer AG; Leverkusen Germany
| | - F. Margheriti
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - G. Gritti
- USC Ematologia; Ospedale Papa Giovanni XXIII; Bergamo Italy
| | - D. Rossi
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - A. Stathis
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - N. Liu
- Pharmaceuticals Division - Therapeutic Research Groups Oncology; Bayer AG; Leverkusen Germany
| | - E. Zucca
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - O. Politz
- Pharmaceuticals Division - Therapeutic Research Groups Oncology; Bayer AG; Leverkusen Germany
| | - F. Bertoni
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| |
Collapse
|
|
7
|
Spriano F, Tarantelli C, Golino G, Gaudio E, Scalise L, Cascione L, Zucca E, Van Berkel P, Stathis A, Zammarchi F, Bertoni F. THE ANTI-CD25 ANTIBODY-DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT-301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES. Hematol Oncol 2019. [DOI: 10.1002/hon.134_2630] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- F. Spriano
- Institute of Oncology Research; Università della Svizzera italiana; Bellinzona Switzerland
| | - C. Tarantelli
- Institute of Oncology Research; Università della Svizzera italiana; Bellinzona Switzerland
| | - G. Golino
- Institute of Oncology Research; Università della Svizzera italiana; Bellinzona Switzerland
| | - E. Gaudio
- Institute of Oncology Research; Università della Svizzera italiana; Bellinzona Switzerland
| | - L. Scalise
- Institute of Oncology Research; Università della Svizzera italiana; Bellinzona Switzerland
| | - L. Cascione
- Institute of Oncology Research; Università della Svizzera italiana; Bellinzona Switzerland
| | - E. Zucca
- Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - P. Van Berkel
- Pharmacology; ADC Therapeutics; London United Kingdom
| | - A. Stathis
- Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Zammarchi
- Pharmacology; ADC Therapeutics; London United Kingdom
| | - F. Bertoni
- Institute of Oncology Research; Università della Svizzera italiana; Bellinzona Switzerland
| |
Collapse
|
|
8
|
Spriano F, Gaudio E, Tarantelli C, Golino G, Cascione L, Zucca E, Stathis A, Giles F, Bertoni F. SIMULTANEOUS BET/CREBBP/EP300 TARGETING APPROACH COMPARED TO SINGLE BET OR CREBBP/EP300 INHIBITION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). Hematol Oncol 2019. [DOI: 10.1002/hon.196_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- F. Spriano
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - E. Gaudio
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - C. Tarantelli
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - G. Golino
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - L. Cascione
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - E. Zucca
- Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Stathis
- Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Giles
- Developmental Therapeutics Consortium; Chicago United States
| | - F. Bertoni
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| |
Collapse
|
|
9
|
Gaudio E, Spriano F, Tarantelli C, Guala M, Riveiro E, Golino G, Lupia A, Costa G, Rocca R, Cascione L, Jenni S, Tsai Y, Bornhauser B, Alcaro S, Paduano F, Trapasso F, Zucca E, Stathis A, Pazzi N, Cavalli F, Bertoni F. EG-011 IS A NOVEL SMALL MOLECULE WITH IN VITRO
AND IN VIVO
ANTI-TUMOR ACTIVITY AGAINST LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.197_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- E. Gaudio
- Università della Svizzera Italiana; Institute of Oncology Research; Bellinzona Switzerland
| | - F. Spriano
- Università della Svizzera Italiana; Institute of Oncology Research; Bellinzona Switzerland
| | - C. Tarantelli
- Università della Svizzera Italiana; Institute of Oncology Research; Bellinzona Switzerland
| | | | - E. Riveiro
- Early Drug Development Group; ris France
| | - G. Golino
- University “Magna Graecia” of Catanzaro; Catanzaro Italy
| | - A. Lupia
- University “Magna Graecia” of Catanzaro; Catanzaro Italy
| | - G. Costa
- University “Magna Graecia” of Catanzaro; Catanzaro Italy
| | - R. Rocca
- University “Magna Graecia” of Catanzaro; Catanzaro Italy
| | - L. Cascione
- Università della Svizzera Italiana; Institute of Oncology Research; Bellinzona Switzerland
| | - S. Jenni
- Children's Hospital Zurich; Zurich Switzerland
| | - Y. Tsai
- Children's Hospital Zurich; Zurich Switzerland
| | | | - S. Alcaro
- University “Magna Graecia” of Catanzaro; Catanzaro Italy
| | - F. Paduano
- University “Magna Graecia” of Catanzaro; Catanzaro Italy
| | - F. Trapasso
- University “Magna Graecia” of Catanzaro; Catanzaro Italy
| | - E. Zucca
- Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Stathis
- Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | | | - F. Cavalli
- Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Bertoni
- Università della Svizzera Italiana; Institute of Oncology Research; Bellinzona Switzerland
| |
Collapse
|
|
10
|
Spriano F, Chung E, Napoli S, Tarantelli C, Gaudio E, Cascione L, Cavalli A, Rinaldi A, Kwee I, Ye H, Rossi D, Zucca E, Stathis A, Jessen K, Lannutti B, Toretsky J, Bertoni F. THE FIRST-IN-CLASS ETS INHIBITOR TK-216 INTERFERES WITH ETS TRANSCRIPTION FACTORS AND SYNERGIZE WITH LENALIDOMIDE IN LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.132_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- F. Spriano
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - E. Chung
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - S. Napoli
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - C. Tarantelli
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - E. Gaudio
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - L. Cascione
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - A. Cavalli
- Institute for Research in Biomedicine; Università della Svizzera italiana; Bellinzona Switzerland
| | - A. Rinaldi
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - I. Kwee
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - H. Ye
- Department of Cell Biology; Albert Einstein College of Medicine and Montefiore Medical Center; New York United States
| | - D. Rossi
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - E. Zucca
- Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Stathis
- Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - K. Jessen
- Oncternal Therapeutics; San Diego; United States
| | - B. Lannutti
- Oncternal Therapeutics; San Diego; United States
| | - J. Toretsky
- Departments of Oncology and Pediatrics; Lombardi Comprehensive Cancer Center, Georgetown University; Washington D.C. United States
| | - F. Bertoni
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| |
Collapse
|
|
11
|
Arribas A, Napoli S, Gaudio E, Cascione L, Di Veroli A, Tarantelli C, Spriano F, Zucchetto A, Rossi F, Rinaldi A, Stathis A, Stussi G, Gattei V, Cruciani G, Zucca E, Rossi D, Bertoni F. MECHANISMS OF SECONDARY RESISTANCE TO IDELALISIB IN MARGINAL ZONE LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.128_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- A. Arribas
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - S. Napoli
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - E. Gaudio
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - L. Cascione
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - A. Di Veroli
- Department of Chemistry; Biology and Biotechnology, University of Perugia; Perugia Italy
| | - C. Tarantelli
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - F. Spriano
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - A. Zucchetto
- Centro di Riferimento Oncologico di Aviano; Centro di Riferimento Oncologico di Aviano - CRO; Aviano Italy
| | - F. Rossi
- Centro di Riferimento Oncologico di Aviano; Centro di Riferimento Oncologico di Aviano - CRO; Aviano Italy
| | - A. Rinaldi
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - A. Stathis
- Oncology Institute of Southern Switzerland; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - G. Stussi
- Oncology Institute of Southern Switzerland; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - V. Gattei
- Centro di Riferimento Oncologico di Aviano; Centro di Riferimento Oncologico di Aviano - CRO; Aviano Italy
| | - G. Cruciani
- Department of Chemistry; Biology and Biotechnology, University of Perugia; Perugia Italy
| | - E. Zucca
- Oncology Institute of Southern Switzerland; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - D. Rossi
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| | - F. Bertoni
- Institute of Oncology Research; Università della Svizzera Italiana; Bellinzona Switzerland
| |
Collapse
|
|
12
|
Gaudio E, Kwee I, Spriano F, Tarantelli C, Rinaldi A, Jourdan T, Berthold M, Arribas A, Stathis A, Rossi D, Liu N, Lange M, Politz O, Zucca E, Bertoni F. COMBINATORIAL SCREENING OF THE PI3K INHIBITOR COPANLISIB IN T CELL LYMPHOMAS. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- E. Gaudio
- IOR Institute of Oncology Research; Bellinzona Switzerland
| | - I. Kwee
- IOR Institute of Oncology Research; Bellinzona Switzerland
| | - F. Spriano
- IOR Institute of Oncology Research; Bellinzona Switzerland
| | - C. Tarantelli
- IOR Institute of Oncology Research; Bellinzona Switzerland
| | - A. Rinaldi
- IOR Institute of Oncology Research; Bellinzona Switzerland
| | - T. Jourdan
- Drug Discovery, Pharmaceuticals, Bayer AG; Berlin Germany
| | - M. Berthold
- Drug Discovery, Pharmaceuticals, Bayer AG; Berlin Germany
| | - A. Arribas
- Drug Discovery, Pharmaceuticals, Bayer AG; Berlin Germany
| | - A. Stathis
- IOSI Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - D. Rossi
- IOR Institute of Oncology Research; Bellinzona Switzerland
| | - N. Liu
- Drug Discovery, Pharmaceuticals, Bayer AG; Berlin Germany
| | - M. Lange
- Drug Discovery, Pharmaceuticals, Bayer AG; Berlin Germany
| | - O. Politz
- Drug Discovery, Pharmaceuticals, Bayer AG; Berlin Germany
| | - E. Zucca
- IOSI Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Bertoni
- IOR Institute of Oncology Research; Bellinzona Switzerland
| |
Collapse
|
|
13
|
Gaudio E, Tarantelli C, Spriano F, Bernasconi E, Targa A, Dirnhofer S, Stathis A, Zucca E, Bertoni F. The novel BTK and PI3K-delta inhibitors acalabrutinib (ACP-196) and ACP-319 show activity in pre-clinical B-cell lymphoma models. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32699-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
|
14
|
Arribas A, Rinaldi A, Spriano F, Tarantelli C, Gaudio E, Bernasconi E, Hillmann P, Kwee I, Stathis A, Fabbro D, Stüssi G, Zucca E, Rossi D, Cmiljanovic V, Bertoni F. PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL). Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32697-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
|
15
|
Ricci F, Brunelli L, Spriano F, Pastorelli R, Damia G. Ovarian cancer patient-derived xenografts resistant to cisplatin exhibit metabolic changes. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61154-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|